ClinicalTrials.gg
CompletedNCT01049022Updated Jul 22, 2015

Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients

A Phase 1 interventional study of Moxifloxacin (Avelox, BAY12-8039) and Moxifloxacin (Avelox, BAY12-8039) in Infections, sponsored by Bayer. Completed at 11 sites in United States. Open to participants aged 3 Months to 14 Years. Per ClinicalTrials.gov, last updated 2015-07-22.

Sponsored by Bayer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
3 Months to 14 Years
Sex
All
01

Study summary

The purpose of this study is to describe the pharmacokinetics of moxifloxacin in children to see what the best dose should be for children in the future. Pharmacokinetics is to see how the body absorbs, distributes, breaks down and gets rid of the study drug. The pharmacokinetics of certain drugs may be altered in children due to developmental differences in various organ functions responsible for drug elimination, as well as in general distribution characteristics. The safety of moxifloxacin in children with infections will also be looked at. Results from this study will be used to guide dosing strategies of the larger clinical trial planned for children

02

Conditions studied

  • Infections

Browse trials for

Keywords

  • Pharmacokinetics
03

In context

Infections

2,096 studies on the registry are indexed under Infections; 364 are open to participants now.

This study's enrollment of 31 is below the median of 113 across 1,305 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Months to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females, ages 3 months through 14 years inclusive
  • Receiving antibiotics for suspected or proven infection

Exclusion criteria

Exclusion Criteria:

  • Body weight greater than 45 kg
  • Patients taking anti-seizure medications within 30 days of moxifloxacin dosing
  • Known or suspected allergy to quinolones
  • History of tendon disease/disorder related to quinolone treatment
  • Severe, life-threatening disease with a of less than 48 hours and/or known rapidly fatal underlying disease (death expected within 2 months)
  • Abnormal musculoskeletal evaluation at baseline assessment; or chronic musculoskeletal disease (eg, juvenile rheumatoid arthritis); or chronic illness with high risk for chronic or recurrent arthritis or tendinitis (eg, cystic fibrosis, chronic inflammatory bowel disease)
  • Cardiac arrhythmia
  • Evidence of renal or hepatic disease, based on laboratory findings (serum creatinine, total , or , > 1.5 times ) and physical exam
  • Patients receiving Class IA (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic agents
  • Patients taking any medication known to increase the , eg, amiodarone, astemizole, bepridil, chloroquine, chlorpromazine, cisapride, disopyuramide, dofetilide, droperidol, halofantrine, haloperidol, ibutilide, levomethadyl, mesoradazine, methadone, pimozide, procainamide, quinidine, sotalol, terfenadine
  • Pregnancy
  • findings in the
  • Participation in another clinical study during the preceding 30 days1 (last treatment from previous study to first treatment of new study)
  • Criteria which in the opinion of the investigator preclude participation for scientific reasons, for reasons of compliance, or for reasons of the patient's safety
  • Patients taking another fluoroquinolone at the time of planned moxifloxacin dosing
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Moxifloxacin (Avelox, BAY12-8039), Cohort 1

    Drug: Moxifloxacin (Avelox, BAY12-8039)

  • Experimental
    Moxifloxacin (Avelox, BAY12-8039), Cohort 2

    Drug: Moxifloxacin (Avelox, BAY12-8039)

  • Experimental
    Moxifloxacin (Avelox, BAY12-8039), Cohort 3

    Drug: Moxifloxacin (Avelox, BAY12-8039)

Interventions

  • Single intravenous (IV) infusion of moxifloxacin administered over 60 minutes, at an initial dosage of 5 milligram per kilogram per body weight (mg/kg/BW) with dose escalation to 6 mg/kg in subjects of age 6 years (yrs) to less than or equal to (\<=) 14 years.

  • Single IV infusion of moxifloxacin administered over 60 minutes, at a dosage of 7 mg/kg/BW with dose escalation to 8 mg/kg in subjects of age 2 years to less than (\<) 6 years; dose escalation was based on evaluations of the pharmacokinetic (PK) and safety data from the subjects in a preceding cohort.

  • Single IV infusion of moxifloxacin administered over 60 minutes, at a dosage of 9 mg/kg/BW with dose escalation to 10 mg/kg in subjects of age 3 months to \< 2 years; dose escalation was based on evaluations of the PK and safety data from the subjects in a preceding cohort.

06

What researchers measure

Primary outcomes

  1. Area under the Concentration-Time Curve (AUC) of Moxifloxacin and its Metabolites

    The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.

    Time frame: Pre-dose, 1 hour (end of infusion), 1.5, 4, 8, 12 and 24 hours (Day 2) after start of infusion (samples at 36 h and 48 h were optional)

  2. Maximum Observed Drug Concentration in Plasma (Cmax) of Moxifloxacin and its Metabolites

    Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.

    Time frame: Pre-dose, 1 hour (end of infusion), 1.5, 4, 8, 12 and 24 hours (Day 2) after start of infusion (samples at 36 h and 48 h were optional)

  3. Number of Subjects With Treatment Emergent Findings on Joint Assessment: Baseline

    Joint assessment included formal physical examination of all joints with special care and attention to the weight-bearing joints (such as, knees, hips, and ankles) and to the shoulder girdle. All joints were examined for pain/tenderness, evidence of inflammation (i.e., redness, warmth, deformity, swelling or ballotable fluid), loss of function (to the extent this could be assessed in younger children and infants), and any restrictions to expected active/passive range of motion. An incidence count was reported as the number of subjects with at least one finding at baseline, regardless of side.

    Time frame: Baseline

  4. Number of Subjects With Treatment Emergent Findings on Joint Assessment : At any Time During Treatment

    Joint assessment included formal physical examination of all joints with special care and attention to the weight-bearing joints (such as, knees, hips, and ankles) and to the shoulder girdle. An incidence count was reported as the number of subjects with at least one finding at any time during treatment, regardless of side.

    Time frame: Day 1 up to Year 5 (follow-up)

Secondary outcomes

  1. Time to Reach Maximum Drug Concentration in Plasma (tmax) of Moxifloxacin and its Metabolites

    tmax refers to the time after dosing when a drug attains its highest measurable concentration (Cmax). It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.

    Time frame: Pre-dose, 1 hour (end of infusion), 1.5, 4, 8, 12 and 24 hours (Day 2) after start of infusion (samples at 36 h and 48 h were optional)

  2. Half Life Associated With Terminal Slope (t1/2) of Moxifloxacin and its Metabolites

    Half life associated with terminal slope refers to the elimination of the drug. It is the time taken for the blood plasma concentration to reach half the concentration in the terminal phase of elimination. It is expressed in hours (h) and derived from the terminal slope of the concentration versus time curve.

    Time frame: Pre-dose, 1 hour (end of infusion), 1.5, 4, 8, 12 and 24 hours (Day 2) after start of infusion (samples at 36 h and 48 h were optional)

  3. Total Amount Excreted in the Urine (Aeur) of Moxifloxacin and its Metabolites

    Aeur refers to the total amount of moxifloxacin excreted in urine.

    Time frame: Baseline up to 36 hour post-infusion

  4. Volume of Distribution at Steady State (Vss) of Moxifloxacin and its Metabolites

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Vss is the apparent volume of distribution at steady-state.

    Time frame: Pre-dose, 1 hour (end of infusion), 1.5, 4, 8, 12 and 24 hours (Day 2) after start of infusion (samples at 36 h and 48 h were optional)

  5. Plasma Clearance (CL) of Moxifloxacin and its Metabolites

    Total body clearance of drug in plasma is expressed in litres per hour.

    Time frame: Pre-dose, 1 hour (end of infusion), 1.5, 4, 8, 12 and 24 hours (Day 2) after start of infusion (samples at 36 h and 48 h were optional)

  6. Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity Divided by Dose Per kilogram Body Weight (AUCnorm) of Moxifloxacin and its Metabolites

    AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. AUCnorm is defined as AUC divided by dose per kg body weight.

    Time frame: Pre-dose, 1 hour (end of infusion), 1.5, 4, 8, 12 and 24 hours (Day 2) after start of infusion (samples at 36 h and 48 h were optional)

  7. Maximum Observed Plasma Concentration Divided by Dose Per kilogram Body Weight (Cmax,Norm) of Moxifloxacin and its Metabolites

    Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample. Cmax,norm is defined as Cmax divided by dose (mg) per kg body weight.

    Time frame: Pre-dose, 1 hour (end of infusion), 1.5, 4, 8, 12 and 24 hours (Day 2) after start of infusion (samples at 36 h and 48 h were optional)

07

Study locations

11 sites
  • Little Rock, Arkansas 72202, United States
  • Orange, California 92868-3974, United States
  • San Diego, California 92123-4282, United States
  • Louisville, Kentucky 40202, United States
  • New Orleans, Louisiana 70118-5799, United States
  • Boston, Massachusetts 02115, United States
  • Kansas City, Missouri 64108-9898, United States
  • Cincinnati, Ohio 45229-3039, United States
  • Cleveland, Ohio 44106, United States
  • Toledo, Ohio 43606, United States
  • Salt Lake City, Utah 84132, United States
08

References and documents

Publications

  • Wirth S, Emil SGS, Engelis A, Digtyar V, Criollo M, DiCasoli C, Stass H, Willmann S, Nkulikiyinka R, Grossmann U; MOXIPEDIA Study Group. Moxifloxacin in Pediatric Patients With Complicated Intra-abdominal Infections: Results of the MOXIPEDIA Randomized Controlled Study. Pediatr Infect Dis J. 2018 Aug;37(8):e207-e213. doi: 10.1097/INF.0000000000001910. PubMed 29356761 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of Dec 2012 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2010
First posted
Jan 14, 2010
Start
May 2010
Primary completionActual
Dec 2012
CompletionActual
Aug 2013
Last update
Jul 22, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01049022
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jan 14, 2010
Start date
May 2010
Primary completion
Dec 2012
Completion
Aug 2013
Last update
Jul 22, 2015

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxifloxacin

Start the discussion